MA55766A - Nanoparticules lipidiques - Google Patents

Nanoparticules lipidiques

Info

Publication number
MA55766A
MA55766A MA055766A MA55766A MA55766A MA 55766 A MA55766 A MA 55766A MA 055766 A MA055766 A MA 055766A MA 55766 A MA55766 A MA 55766A MA 55766 A MA55766 A MA 55766A
Authority
MA
Morocco
Prior art keywords
lipid nanoparticles
nanoparticles
lipid
Prior art date
Application number
MA055766A
Other languages
English (en)
French (fr)
Inventor
James Heyes
Adam Judge
Kieu Mong Lam
Alan D Martin
Original Assignee
Genevant Sciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genevant Sciences Gmbh filed Critical Genevant Sciences Gmbh
Publication of MA55766A publication Critical patent/MA55766A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MA055766A 2019-04-26 2020-04-24 Nanoparticules lipidiques MA55766A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962839452P 2019-04-26 2019-04-26
US201962867098P 2019-06-26 2019-06-26

Publications (1)

Publication Number Publication Date
MA55766A true MA55766A (fr) 2022-03-02

Family

ID=72941858

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055766A MA55766A (fr) 2019-04-26 2020-04-24 Nanoparticules lipidiques

Country Status (8)

Country Link
US (1) US20220168222A1 (https=)
EP (1) EP3959314A4 (https=)
JP (1) JP2022530018A (https=)
CN (1) CN114026233A (https=)
AU (1) AU2020262437A1 (https=)
CA (1) CA3137450A1 (https=)
MA (1) MA55766A (https=)
WO (1) WO2020219941A1 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021005462A (es) * 2018-11-09 2021-08-24 Arbutus Biopharma Corp Lipidos cationicos que contienen silicio.
KR20220121246A (ko) 2019-12-20 2022-08-31 큐어백 아게 핵산 전달용 신규한 지질 나노입자
US12023376B1 (en) 2020-04-17 2024-07-02 Triad National Security, Llc Conserved region T cell vaccines for coronavirus and methods of use
AU2021305214A1 (en) * 2020-07-10 2023-02-23 Genevant Sciences Gmbh Lipid nanoparticles for delivering therapeutics to lungs
CN116234917A (zh) 2020-07-27 2023-06-06 安杰瑞姆生物科学公司 Dna分子组合物及其制备方法和使用方法
CZ310613B6 (cs) 2020-09-23 2026-01-28 Ústav organické chemie a biochemie AV ČR, v. v. i. Lipidoidy pro transfekci nukleových kyselin a jejich použití
JP2023546175A (ja) 2020-10-14 2023-11-01 ジョージ・メイソン・リサーチ・ファウンデーション・インコーポレイテッド 脂質ナノ粒子製造の方法及びそれに由来する組成物
WO2022099003A1 (en) 2020-11-06 2022-05-12 Sanofi Lipid nanoparticles for delivering mrna vaccines
IL303195A (en) 2020-11-25 2023-07-01 Akagera Medicines Inc Lipid nanoparticles for delivery of nucleic acids and related methods of use
AU2021403156A1 (en) * 2020-12-18 2023-07-13 Genevant Sciences Gmbh Peg lipids and lipid nanoparticles
WO2022198229A1 (en) * 2021-03-17 2022-09-22 Board Of Regents Of The University Of Nebraska Lipid nanoparticle formulations and methods of use thereof
EP4323525A2 (en) 2021-04-16 2024-02-21 Genentech, Inc. Optimized tlr7 ligands and uses thereof
CZ310443B6 (cs) 2021-07-19 2025-06-25 Ústav organické chemie a biochemie AV ČR, v. v. i. Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití
WO2023031392A2 (en) 2021-09-03 2023-03-09 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
US20250027107A1 (en) 2021-10-18 2025-01-23 Flagship Pioneering Innovations Vii, Llc Dna compositions and related methods
KR20230061895A (ko) * 2021-10-29 2023-05-09 주식회사 아이큐어비앤피 지질 나노입자 및 세포 투과성을 갖는 신규 펩타이드의 복합체
WO2023218431A1 (en) 2022-05-13 2023-11-16 BioNTech SE Rna compositions targeting hiv
CN117203186A (zh) * 2022-05-13 2023-12-08 南方科技大学 一种含有二硫键的脂质化合物及其组合物
AU2023275457A1 (en) 2022-05-23 2024-11-28 Astrazeneca Ab Gene therapy compositions and methods of use thereof
KR20250021330A (ko) 2022-05-25 2025-02-12 비온테크 에스이 원숭이두창 항원 전달을 위한 rna 조성물 및 관련 방법
EP4531819A2 (en) 2022-05-25 2025-04-09 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
US20250375534A1 (en) 2022-05-30 2025-12-11 BioNTech SE Complexes for delivery of nucleic acids
TWI858802B (zh) * 2022-07-06 2024-10-11 南韓商綠十字股份有限公司 使用陽離子膽固醇用於核酸遞送的局部遞送的脂質納米顆粒
EP4562154A2 (en) 2022-07-29 2025-06-04 Massachusetts Institute of Technology COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE SIGNAL REGULATORY PROTEIN ALPHA (SIRPalpha) GENE
WO2024037577A1 (en) * 2022-08-18 2024-02-22 Suzhou Abogen Biosciences Co., Ltd. Composition of lipid nanoparticles
WO2024057237A1 (en) 2022-09-16 2024-03-21 Pfizer Inc. Lipid nanoparticles
EP4342460A1 (en) 2022-09-21 2024-03-27 NovoArc GmbH Lipid nanoparticle with nucleic acid cargo
WO2024131810A1 (en) * 2022-12-21 2024-06-27 Suzhou Abogen Biosciences Co., Ltd. Lipid nanoparticles comprising sterol-modified phospholipids
WO2024141955A1 (en) 2022-12-28 2024-07-04 BioNTech SE Rna compositions targeting hiv
EP4410316A1 (en) * 2023-02-01 2024-08-07 4basebio UK Ltd Nanoparticles for delivery of nucleic acid cargos
AU2024217077A1 (en) * 2023-02-06 2025-09-18 University Of Tennessee Research Foundation Multi-functional lipid nanoparticles and uses thereof
WO2024205499A1 (en) * 2023-03-27 2024-10-03 Agency For Science, Technology And Research A compound for preparing lipid nanoparticles encapsulating an agent, nanoparticle composition comprising said compound and related methods thereof
WO2024259158A2 (en) * 2023-06-13 2024-12-19 Cornell University Lipid nanoparticles for peptide delivery and methods of making and using the same
CN121866336A (zh) 2023-08-03 2026-04-14 百欧恩泰欧洲股份公司 靶向hiv的rna组合物
WO2025027579A2 (en) 2023-08-03 2025-02-06 BioNTech SE Rna compositions targeting hiv
IL326647A (en) 2023-09-01 2026-04-01 Novoarc Gmbh Lipid nanoparticles with a nucleic acid charge and an ionizable lipid
WO2025124711A1 (en) 2023-12-13 2025-06-19 BioNTech SE Glycolipid compositions
WO2025219570A1 (en) 2024-04-17 2025-10-23 Johannes Kepler Universität Linz Composition for inhibiting protein translocation and methods using the same
WO2025242657A1 (en) 2024-05-21 2025-11-27 Shape Biopharmaceuticals Ag Lipopeptide building blocks and aggregates
GB202408360D0 (en) 2024-06-11 2024-07-24 Cancer Research Tech Ltd Tumour sensitisation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20220652T1 (hr) * 2015-12-10 2022-06-24 Modernatx, Inc. Pripravci i postupci unosa terapijskih sredstava
CN109563511A (zh) * 2016-06-30 2019-04-02 阿布特斯生物制药公司 用于递送信使rna的组合物和方法

Also Published As

Publication number Publication date
EP3959314A1 (en) 2022-03-02
US20220168222A1 (en) 2022-06-02
CN114026233A (zh) 2022-02-08
JP2022530018A (ja) 2022-06-27
WO2020219941A1 (en) 2020-10-29
CA3137450A1 (en) 2020-10-29
EP3959314A4 (en) 2023-02-08
AU2020262437A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
MA55766A (fr) Nanoparticules lipidiques
EP3877521A4 (en) LIPID DNA NOPARTICLE FORMULATIONS
EP3877522A4 (en) LIPID DNA NOPARTICLE FORMULATIONS
EP3967649A4 (en) LIPIDNANOPARTICLES
DK3532103T3 (da) Formuleringer af lipid-nanopartikler
EP3645767A4 (en) MAGNETIC NANOPARTICLE
EP2968510A4 (en) COMPOSITIONS OF NANOPARTICLES
DK3835287T3 (da) Kationisk lipid
JP2016502162A5 (https=)
EP2981285A4 (en) NOVEL NANOPARTICLE COMPOSITIONS
EP3313381A4 (en) BIOMARKERS FOR NANOPARTICLE COMPOSITIONS
EP4201400A4 (en) LIPID DNANOPARTICLES
EP3959195C0 (en) THIOESTER CATIONIC LIPIDS
EP3887350A4 (en) SOLID LIPID DNA NOPARTICLES OF CURCUMIN
IL281425A (en) Nanoparticle formulations
IL283458A (en) Nanoparticles comprising tacrolimus
DK3946179T4 (da) Stomiposer
EP3668705C0 (en) ADDITIVE MANUFACTURING
EP3558864A4 (en) NANOPARTICLES
MA43648A (fr) Conjugués de nanoparticules
EP3986832A4 (en) Polyester polymer nanocomposites
EP3534909A4 (en) POLYMANANOPARTICLE
EP3830021A4 (en) Tetrahexahedra nanoparticles
EP3512503A4 (en) Liposomal formulations
PL3645513T3 (pl) Pochodne benzoazepiny